FH and cancer: Overall, in the BRCA-negative group, there was a difference of 52.8 MN/1000 (s.e. 14.6; 95% CL 23.8–81.8; P<0.001) between negative BRCA patients with FH positive and controls (subjects without cancer, BRCA negatives and with negative FH for BC).